{"schema_version":"secwatch.filing_event.v1","accession":"0001161697-22-000375","form_type":"8-K","ticker":"KRMD","cik":"0000704440","company_name":"KORU Medical Systems, Inc.","filed_at":"2022-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.950117+00:00","generated_at":"2026-06-24T05:30:57.048105+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"KORU Medical Q2 net sales up 18.4% to $6.5M; raises FY revenue guidance but lowers margin forecast","bullets":["Net sales $6.5M (+18.4% YoY) driven by novel therapies (NRE milestone) and core growth; backorders $0.3M.","GAAP net loss $2.9M (EPS -$0.07) vs $1.1M loss a year ago; adjusted EPS -$0.06.","Raises FY 2022 revenue guidance to $27.0–27.5M (from $26.5–27.0M); lowers gross margin guidance to 55–60% (from 60%).","Manufacturing transfer to contract manufacturer delayed to Q1 2023 (from Q4 2022); cash $18.3M at quarter end.","Expanded novel therapies pipeline with two new biopharmaceutical agreements."],"urls":{"canonical":"https://secwatch.observer/filing/0001161697-22-000375","json":"https://secwatch.observer/filing/0001161697-22-000375.json","markdown":"https://secwatch.observer/filing/0001161697-22-000375.md","text":"https://secwatch.observer/filing/0001161697-22-000375.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/704440/000116169722000375/0001161697-22-000375-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/704440/000116169722000375/form_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T05:30:57.048105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}